MDL | MFCD00666806 |
---|---|
Molecular Weight | 264.28 |
Molecular Formula | C17H12O3 |
SMILES | O=C1C2=C(C=CC=C2)C(C3=CC=C(CC=C)C(O)=C13)=O |
R162 is a potent inhibitor of glutamate dehydrogenase 1 ( GDH1 / GLUD1 ), with anti-cancer properties.
Inhibition of GDH1 activity by R162 treatment results in decreased intracellular fumarate levels, attenuated GPx activity, increased ROS levels, and reduced cell proliferation in H1299 and MDA-MB231 cells, which can be significantly rescued by methyl-α-KG treatment as well as by antioxidant NAC. R162 inhibits cell proliferation and tumor growth potential of human cancer cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
R162 (30 mg/kg/day, i.p.) does not result in a significant histopathological change between the vehicle-treated and R162-treated groups, nor alters complete blood counts, or hematopoietic properties in xenograft tumor mouse models. R162 (20 mg/kg/day) results in significantly decreased tumor growth and masses in mice compared with control mice and effectively inhibits GDH1 activity in resected tumors from xenograft nude mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMF : 6.25 mg/mL ( 23.65 mM ; ultrasonic and warming and heat to 60°C)
DMSO : 5.2 mg/mL ( 19.68 mM ; Need ultrasonic)
Ethanol : 2 mg/mL ( 7.57 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (ultrasonic) (insoluble)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.7839 mL | 18.9193 mL | 37.8387 mL |
5 mM | 0.7568 mL | 3.7839 mL | 7.5677 mL |
10 mM | 0.3784 mL | 1.8919 mL | 3.7839 mL |